Know a great AI tool or AI news source? Submit it to AiByts
Foley Hoag1 min read

Could new US investment curbs complicate China’s biotech licensing surge?

Chinese biotech firms face fresh headwinds in their global expansion as Washington’s proposed outbound investment restrictions threaten to disrupt deal structures, even though drug licensing agreements remain untouched for now, analysts say.

By Xinmei ShenSouth China Morning Post Tech
Could new US investment curbs complicate China’s biotech licensing surge?

Read the full story

Originally published by South China Morning Post Tech on Oct 26, 2026.

Read on South China Morning Post Tech(opens in a new tab)

Comments

Sign in to join the discussion.

No comments yet — be the first to share your thoughts.